InvestorsHub Logo
Followers 971
Posts 383037
Boards Moderated 6
Alias Born 06/24/2011

Re: None

Tuesday, 01/10/2023 8:22:54 AM

Tuesday, January 10, 2023 8:22:54 AM

Post# of 2792
"Closing enrollment for this final cohort of our Phase I trial is a tremendous milestone that marks the start of our preparation for Phase II research," noted Nascent CEO, Sean Carrick. "This is a significant accomplishment in the advancement of our Biologic asset and in our mission to help future patients in their battle against this terrible disease."

$NBIO
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NBIO News